

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2006:315123 CAPLUS Full-text

DN 144:460321

TI Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead

AU Williams, Theresa M.; Stump, Craig A.; Nguyen, Diem N.; Quigley, Amy G.; Bell, Ian M.; Gallicchio, Steven N.; Zartman, C. Blair; Wan, Bang-Lin; Della Penna, Kimberly; Kunapuli, Priya; Kane, Stefanie A.; Koblan, Ken S.; Mosser, Scott D.; Rutledge, Ruth Z.; Salvatore, Christopher; Fay, John F.; Vacca, Joseph P.; Graham, Samuel L.

CS Department of Medicinal Chemistry, Merck & Co., West Point, PA, 19486, USA

SO Bioorganic & Medicinal Chemistry Letters (2006), 16(10), 2595-2598

CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier B.V.

DT Journal

LA English

OS CASREACT 144:460321

AB High-throughput screening of the Merck sample collection identified a benzodiazepinone tetralin-spirohydantoin as a CGRP receptor antagonist with micromolar activity. Comparing the structure of this compound with those of earlier peptide-based antagonists such as BIBN 4096 BS, a key hydrogen bond donor-acceptor pharmacophore was hypothesized. Subsequent structure activity studies supported this hypothesis and led to benzodiazepinone piperidinyldihydroquinazolinone, CGRP receptor $K_i = 44$ nM and $IC_{50} = 38$ nM. This compound was orally bioavailable in rats and is a lead in the development of orally bioavailable CGRP antagonists for the treatment of migraine.

IT 820214-24-2P


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead in relation to treatment of migraine)

RN 820214-24-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 820214-30-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead in relation to treatment of migraine)

RN 820214-30-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1-(1-methylethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)

(CA INDEX NAME)



IT 820214-20-8P 820214-22-0P 820214-23-1P
820214-52-6P 820214-67-3P 820214-69-5P
886854-33-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(non-peptide calcitonin gene-related peptide receptor antagonists from
a benzodiazepinone lead in relation to treatment of migraine)

RN 820214-20-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-
1-ethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.



RN 820214-22-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-
1,4-benzodiazepin-3-yl]-4-[(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 820214-23-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 820214-52-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-67-3 CAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA


INDEX NAME)



RN 820214-69-5 CAPLUS


CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 886854-33-7 CAPLUS



CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1-(1-methylethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-1-methyl-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2005:14369 CAPLUS Full-text
 DN 142:114110
 TI Preparation of benzodiazepine CGRP receptor antagonists
 IN Burgey, Christopher S.; Stump, Craig A.; Williams, Theresa M.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2005000807	A2	20050106	WO 2004-US20206	20040624	
	WO 2005000807	A3	20060105			
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	AU 2004252150	A1	20050106	AU 2004-252150	20040624	
	CA 2529227	AA	20050106	CA 2004-2529227	20040624	
	EP 1641781	A2	20060405	EP 2004-776996	20040624	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR		
	CN 1812982	A	20060802	CN 2004-80017952	20040624	
	US 2006148790	A1	20060706	US 2005-562298	20051222	
PRAI	US 2003-482674P	P	20030626			
	WO 2004-US20206	W	20040624			
OS	MARPAT 142:114110					
GI						



AB Title compds. I [R1 = H, alk(en/yn)yl, etc.; R2 = H, alkyl, cycloalkyl, etc.; R7 = H, alk(en/yn)yl, etc.; W = O, amino, alkyl; X = C, S; Y = O, NCN, etc.; R3 = H, alkyl, CN, etc.; R6 = H, alkyl, cycloalkyl, etc.; G-J = N, N-alkyl, etc.] are prepared For instance, II is prepared from (R)-3-amino-1-ethyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine oxalate, p-

nitrophenylchloroformate and 3-(piperidin-4-yl)-3,4-dihydroquinazolin-2(1H)-one hydrochloride. Compds. I exhibit affinity for the CGRP receptor with an IC50 of less than 50µM. I, alone or in combination with other agents, are useful for the treatment of diseases in which the CGRP is involved, such as headache, migraine and cluster headache.


IT 820214-20-8P 820214-21-9P 820214-22-0P
 820214-23-1P 820214-24-2P 820214-25-3P
 820214-26-4P 820214-27-5P 820214-28-6P
 820214-29-7P 820214-30-0P 820214-31-1P
 820214-32-2P 820214-33-3P 820214-34-4P
 820214-35-5P 820214-36-6P 820214-37-7P
 820214-38-8P 820214-39-9P 820214-40-2P
 820214-41-3P 820214-42-4P 820214-43-5P
 820214-44-6P 820214-45-7P 820214-46-8P
 820214-47-9P 820214-48-0P 820214-49-1P
 820214-50-4P 820214-51-5P 820214-52-6P
 820214-53-7P 820214-54-8P 820214-55-9P
 820214-57-1P 820214-59-3P 820214-61-7P
 820214-63-9P 820214-65-1P 820214-67-3P
 820214-69-5P 820214-71-9P 820214-73-1P
 820214-75-3P 820214-77-5P 820214-79-7P
 820214-81-1P 820214-84-4P 820214-86-6P
 820214-88-8P 820214-91-3P 820214-93-5P
 820214-95-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of benzodiazepine CGRP receptor antagonists for headaches)

RN 820214-20-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-1-ethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-21-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-4-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[(3R)-1-ethyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-22-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-23-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-24-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-25-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-6-chloro-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-26-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-7-chloro-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-27-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-8-chloro-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-28-6 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-9-chloro-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 820214-29-7 CAPLUS

CN 1-Piperidinecarboxamide, N-(2,3-dihydro-2-oxo-5-phenyl-1-propyl-1H-1,4-benzodiazepin-3-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 820214-30-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1-(1-methylethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 820214-31-1 CAPLUS


CN 1-Piperidinecarboxamide, N-(1-butyl-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 820214-32-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-33-3 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3S)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 820214-34-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-2-oxo-5-phenyl-1-(4,4,4-trifluorobutyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)




RN 820214-35-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[1-(cyclopropylmethyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)




RN 820214-36-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1-[(4-methoxyphenyl)methyl]-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 820214-37-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-2-oxo-5-phenyl-1-(2-pyridinylmethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 820214-38-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-2-oxo-5-phenyl-1-(3-pyridinylmethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 820214-39-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-2-oxo-5-phenyl-1-(4-pyridinylmethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)




RN 820214-40-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 820214-41-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-4-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-1-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 820214-42-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 820214-43-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-4-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)




RN 820214-44-6 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 820214-45-7 CAPLUS


CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-4-hydroxy-2-oxo-3(2H)-quinazolinyl)-N-[5-(3-fluorophenyl)-2,3-dihydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)



RN 820214-46-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-5-cyclohexyl-2,3-dihydro-1-methyl-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-47-9 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-5-(1-methylethyl)-2-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 820214-48-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1,7-dimethyl-5-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 820214-49-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[2,3-dihydro-1,8-dimethyl-5-(1-methylethyl)-2-oxo-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)



RN 820214-50-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-[(3S)-5-(1,1-dimethylethyl)-2,3-dihydro-2-oxo-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-51-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,2-dihydro-2-oxo-3-quinolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-52-6 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 820214-53-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, 2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl ester (9CI) (CA INDEX NAME)




RN 820214-54-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, 2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl ester (9CI) (CA INDEX NAME)




RN 820214-55-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-, 7-chloro-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl ester (9CI) (CA INDEX NAME)




RN 820214-57-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-, 2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl ester (9CI) (CA INDEX NAME)



RN 820214-59-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-, 2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl ester (9CI) (CA INDEX NAME)



RN 820214-61-7 CAPLUS

CN 1-Piperidinecarboximidamide, N-cyano-N'-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-63-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3S)-2,3-dihydro-1-(2-methylpropyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-65-1 CAPLUS


CN 1-Piperidinecarboxamide, N-[(3R)-1-(4-aminobutyl)-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 820214-67-3 CAPLUS


CN 1-Piperidinecarboxamide, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-(9CI) (CA INDEX NAME)



RN 820214-69-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-71-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-5-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-73-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(6-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-75-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-77-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(7-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-79-7 CAPLUS

CN 1-Piperidinecarboxamide, 4-((2,3-dihydro-6-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-81-1 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-[[2,3-dihydro-2-oxo-6-(trifluoromethyl)-1H-benzimidazol-1-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-84-4 CAPLUS

CN 1H-Benzimidazole-5-carboxylic acid, 3-[1-[[[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-86-6 CAPLUS

CN 1H-Benzimidazole-5-carboxamide, 3-[1-[[[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]amino]carbonyl]-4-piperidinyl]-2,3-dihydro-2-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-88-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-[2,3-dihydro-6-(methylsulfonyl)-2-oxo-1H-benzimidazol-1-yl]-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-91-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(5-chloro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-93-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-4-methyl-2-oxo-1H-benzimidazol-1-yl)-N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 820214-95-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-2,3-dihydro-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-1,4-benzodiazepin-3-yl]-4-(5-fluoro-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 820215-30-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzodiazepine CGRP receptor antagonists for headaches)


RN 820215-30-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(3R)-1-[4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)butyl]-2,3-dihydro-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d l2; d his; log y
 L2 HAS NO ANSWERS
 L1 STR



G1 C,O,N
 G2 C,S
 G3 C,N

Structure attributes must be viewed using STN Express query preparation.
 L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 15:30:38 ON 13 SEP 2006)

FILE 'REGISTRY' ENTERED AT 15:31:30 ON 13 SEP 2006

L1 STRUCTURE UPLOADED
 L2 QUE L1
 L3 2 S L2
 L4 57 S L2 FUL

FILE 'CAPLUS' ENTERED AT 15:31:59 ON 13 SEP 2006

L5 2 S L4

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	10.68	178.04
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

STN INTERNATIONAL LOGOFF AT 15:32:51 ON 13 SEP 2006